01 4Feburic
02 6Uloric
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 242
2018 Revenue in Millions : 486
Growth (%) : -50
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 23
2019 Revenue in Millions : 17
Growth (%) : 32
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 32
2019 Revenue in Millions : 247
Growth (%) : -87
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 24
2020 Revenue in Millions : 23
Growth (%) : 12
Main Therapeutic Indication : Rheumatology
Currency : USD
2021 Revenue in Millions : 4
2020 Revenue in Millions : 31
Growth (%) : -85
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 26
2021 Revenue in Millions : 24
Growth (%) : 6
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 18
2018 Revenue in Millions : 18
Growth (%) : 0
Main Therapeutic Indication : Rheumatoid Arthiritis
Currency : USD
2016 Revenue in Millions : 377
2015 Revenue in Millions : 370
Growth (%) : 2
Main Therapeutic Indication : Rheumatoid Arthritis
Currency : USD
2017 Revenue in Millions : 444
2016 Revenue in Millions : 402
Growth (%) : 10
Main Therapeutic Indication : Autoimmune Disorders
Currency : USD
2018 Revenue in Millions : 471
2017 Revenue in Millions : 416
Growth (%) : 13%
LOOKING FOR A SUPPLIER?